Cargando…
Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-related markers on the tumour and its associated tumour...
Autores principales: | Goode, Emily F., Roussos Torres, Evanthia T., Irshad, Sheeba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205515/ https://www.ncbi.nlm.nih.gov/pubmed/34141724 http://dx.doi.org/10.3389/fmolb.2021.674558 |
Ejemplares similares
-
Identification and Validation of Immune-Related Gene Signature for Predicting Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma
por: Jia, Ran, et al.
Publicado: (2021) -
Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells
por: Alberts, Elena, et al.
Publicado: (2021) -
Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022) -
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
por: Zhang, Zhizhu, et al.
Publicado: (2021) -
Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma
por: Ying, Haoxuan, et al.
Publicado: (2021)